CollPlant to Begin Trading on Nasdaq Under New Ticker Symbol “OPHI”

CollPlant Biotechnologies (Nasdaq: CLGN) will begin trading under the new ticker symbol OPHI at the market open on November 13, 2026.

Rhea-AI Summary

CollPlant Biotechnologies (Nasdaq: CLGN) will begin trading under the new ticker symbol OPHI at the market open on November 13, 2026. Its ordinary shares will trade under CLGN through the close on November 12, 2026. The Nasdaq listing and CUSIP number will remain unchanged, and shareholders need not take any action.

The company said the ticker change reflects its expansion into photonic computing built around LightSolver’s all-optical Laser Processing Unit technology. CollPlant also intends to rename itself OptiPhi Computing, subject to shareholder approval at the November 24, 2026 extraordinary general meeting and consent from the Israeli Registrar of Companies.

Argus 15 min delay 5 alerts

+8.59% vs previous close $4.30 last price 5.5x rel. volume Open Argus

Details

Market move: CLGN +8.59% vs previous close. Nasdaq ticker change

$4.15 – $4.35 Day Range

$13.22M Mkt Cap at Last Price

On Nov 12, the day this news came out, the latest delayed price for CLGN is 8.59% above the previous close. Our momentum scanner has recorded 5 alerts for this stock so far that day. The latest delayed price is $4.30. Relative volume is exceptionally heavy at 5.5x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

OPHI ticker effective date: November 13, 2026 Proposed name-change meeting: November 24, 2026

OPHI ticker effective date

November 13, 2026

Trading under OPHI begins at the open

Proposed name-change meeting

November 24, 2026

Shareholder approval and Israeli Registrar consent are required

Key Terms

photonic computing, cusip number, recombinant human collagen, 3d bioprinting

4 terms

photonic computing technical

"reflects our strategic expansion into photonic computing"

Photonic computing uses pulses of light instead of moving electrons to carry out calculations and move information, like replacing electrical wiring with tiny beams of light on a computer chip. It matters to investors because light-based chips promise much faster data processing and lower power use for tasks like large-scale AI and data centers, potentially creating new markets and competitive advantages — but the technology is still emerging and carries development and scaling risks.

cusip number financial

"CollPlant’s CUSIP number will remain unchanged"

A CUSIP number is a nine-character code that uniquely identifies a specific U.S. or Canadian stock, bond, or other security, similar to a barcode or a social-security number for a financial instrument. It matters to investors because it removes confusion between similar securities, ensures trades and settlements are applied to the correct issue, and helps locate official documents and transaction records quickly.

recombinant human collagen medical

"proprietary plant-derived recombinant human collagen (rhCollagen)"

Collagen produced by inserting human collagen genes into cells or microorganisms so they manufacture the same protein sequence found in people; the product is purified from those cultured cells rather than taken from animal tissue. It matters to investors because it is a scalable, standardized source of human-sequence collagen used in medical products (wound care, implants, cosmetics and drug delivery), and its production method affects manufacturing cost, regulatory review, intellectual property and market differentiation—like making a recipe in a factory instead of harvesting it from different farms.

3d bioprinting technical

"for 3D bioprinting of tissues and organs and medical aesthetics"

3D bioprinting is a manufacturing technique that uses printer-like equipment to place living cells and supportive materials layer by layer to create tissues or organ-like structures, similar to building a model one thin slice at a time. It matters to investors because successful bioprinted products could create new medical therapies, reduce lab time and costs, and open markets in drug testing and transplant alternatives, while also carrying long development timelines and regulatory risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

OPHI marks another important step in CollPlant’s strategy to expand and focus its operations built around LightSolver’s all-optical Laser Processing Unit (LPU)™

Rehovot, Israel, Nov. 12, 2026 (GLOBE NEWSWIRE) -- CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) (“CollPlant”) today announced that its ordinary shares will begin trading on Nasdaq under the new ticker symbol “OPHI,” effective at the open of trading on November 13, 2026. The shares will continue to trade under “CLGN” through the close of trading on November 12, 2026.

No action is required by shareholders in connection with the ticker symbol change. The ordinary shares will continue to be listed on Nasdaq and CollPlant’s CUSIP number will remain unchanged.

“Changing our ticker symbol to OPHI reflects our strategic expansion into photonic computing,” said Eran Rotem, Chief Executive Officer and CFO of CollPlant. “By building our future around LightSolver’s LPU technology, we believe we are positioned to address next-generation computing demands and deliver long-term value to our shareholders.”

“As the world’s demand for computing power keeps growing, the industry is looking for fundamentally new approaches,” said Dr. Ruti Ben Shlomi, Co-Founder and CEO of LightSolver. “Our LPU uses interacting lasers to perform the computation itself, with the potential to solve demanding workloads at significantly higher speeds while reducing energy consumption.”

Subject to shareholder approval at CollPlant’s extraordinary general meeting scheduled for November 24, 2026 and the consent of the Israeli Registrar of Companies, CollPlant intends to change its name to OptiPhi Computing Ltd. For additional details, please see CollPlant’s announcement dated November 4, 2026.

About CollPlant
CollPlant (Nasdaq: CLGN) is an innovative technology company operating at the intersection of deep-tech photonic computing and advanced biotechnology. Through its subsidiary LightSolver, CollPlant is advancing the development of proprietary all-optical laser-based computing architectures designed to resolve the world’s most demanding computational bottlenecks across artificial intelligence, aerospace, financial engineering, and high-performance computing. CollPlant also retains its proprietary plant-derived recombinant human collagen (rhCollagen) and bio-ink assets, for 3D bioprinting of tissues and organs and medical aesthetics. For more information about CollPlant, visit www.collplant.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the expected timing of trading of CollPlant’s ordinary shares under the new ticker symbol; the proposed change of CollPlant’s name; the anticipated performance, capabilities and energy efficiency of the LPU; the long-term value of CollPlant’s photonic computing business; and the future prospects, business plans and growth strategies of CollPlant and LightSolver. Forward-looking statements can be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “plan,” “may,” “should,” “could,” “might,” “seek,” “target,” “will,” “project,” “continue,” “potential” and similar expressions or the negative of such terms. These forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the risk that shareholder approval of the proposed name change or the consent of the Israeli Registrar of Companies is not obtained, or that the name approved differs from the proposed name; LightSolver’s ability to scale its technology from prototype to a commercial product; risks associated with integrating LightSolver’s business, operations and personnel; LightSolver’s ability to achieve anticipated technological and commercial milestones; uncertainties regarding market acceptance and adoption of LightSolver’s technology; the ability to develop and commercialize LightSolver’s products and technology successfully; the ability to establish and expand strategic collaborations and commercial relationships; competition and technological developments; intellectual property risks; the availability of capital; CollPlant’s ability to maintain compliance with Nasdaq listing requirements; general market, industry, economic and geopolitical conditions; and other risks and uncertainties described in CollPlant’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 20-F and subsequent Reports on Form 6-K. Forward-looking statements speak only as of the date of this press release. CollPlant undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Investors Contact
CollPlant Biotechnologies
investors@lightsolver.com

Arx Investor Relations
North American Equities Desk
collplant@arxhq.com